North America Acute Pancreatitis Market Forecast to 2030
North America Acute Pancreatitis Market Forecast to 2030 – Regional Analysis – by Offerings (Medications, Diagnosis, and Others), Causes (Gallstones, Alcoholism, Genetic Disorders, Infection, and Others), and End User (Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis Fuels the North America Acute Pancreatitis Market
Pancreatic cancer is the fourth leading cause of cancer-related mortality in Western countries. According to the American Cancer Society, Cancer Facts & Figures 2022, the mortality rate of pancreatic cancer is predicted to be the second highest among all cancer-led mortality rates in the US by 2030. It is more likely to progress if not detected early when the tumor is resectable. According to an article published in the National Library of Medicine in 2021, only ~15% of pancreatic tumors are resectable at diagnosis, limiting five-year survival to 8%. However, the lack of early symptoms results in poor diagnosis and low resectability of these tumors. Acute pancreatitis may cause pancreatic cancer as it is an early symptom of pancreatic cancer, nearly 1% of acute pancreatitis admissions result in pancreatic cancer diagnoses. It takes several months for these patients to be diagnosed with pancreatic cancer after acute pancreatitis is diagnosed, but some suffer longer diagnostic delays due to initial misdiagnosis, which may hinder their recovery. Recurrent occurrence of acute pancreatitis leads to chronic pancreatitis, which may further increase the risk of pancreatic cancer.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, acute pancreatitis leads to ~275,000 hospital admissions each year, and this number has been increasing in the US. ~35–40% of acute pancreatitis cases in the US are due to gallstones, while alcohol consumption is the cause of 30% of cases. Pancreatitis is usually mild in 80% of patients who are admitted, and most can be discharged within a few days of their hospitalization. Acute pancreatitis is associated with a mortality rate of ~2% and has a relapse rate between 0.6% and 5.6%. Alcohol-related pancreatitis has the highest rate of relapse. According to an article published in Lancet Gastroenterology Hepatology in 2022, the global pooled incidence of acute pancreatitis is 34 cases per 100,000 per year. North America has 58.2 cases per 100,000 people per year (the US has 58.2 cases per 100,000 people per year) while Europe has 24.7 and 15.0 cases per 100,000 people in Sweden and Denmark, respectively.
Acute pancreatitis, which causes the release of digestive enzymes into the pancreatic interstitial space instead of the pancreatic duct lumen, could be an early indicator of pancreatic cancer due to tumor obstruction of the pancreatic duct. Acute pancreatitis is a painful condition, so patients seek medical care sooner, which could lead to an early cancer diagnosis. Therefore, rising cases of pancreatic cancer due to acute pancreatitis boosts the growth of the North America acute pancreatitis market.
North America Acute Pancreatitis Market Overview
The North America acute pancreatitis market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period. the North America acute pancreatitis market in North America is expected to grow due to the increasing burden of acute pancreatitis due to increase in cases of gallstones and excessive consumption of alcohol. Also, with an increase in technological advancement in healthcare facilities, the market in North America is expected to grow during the forecast period.
North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
North America Acute Pancreatitis Market Segmentation
The North America acute pancreatitis market is segmented offerings, causes, end user, and country.
Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the North America acute pancreatitis market is segmented into the US, Canada, and Mexico. The US dominated the North America acute pancreatitis market share in 2022.
Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the North America acute pancreatitis market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the North America acute pancreatitis market was valued at US$ 3,209.63 million in 2022 and is expected to reach US$ 5,000.71 million by 2030, registering a CAGR of 5.7% from 2022 to 2030. Rise in pancreatic cancer cases due to acute pancreatitis, rising incidence of diabetes following acute pancreatitis, and advancements in specific acute pancreatitis treatments are among the critical factors attributed to the North America acute pancreatitis market expansion.
Acute pancreatitis is an inflammatory disorder of the pancreas. The condition is associated with increased morbidity and mortality because there is no specific treatment approved to treat it, leaving supportive care as the main course of treatment. A targeted novel treatment strategy that halts disease progression and improves patient outcomes is needed to address the current disease burden of acute and severe acute pancreatitis. An article published in the National Library of Medicine in February 2023 focuses on 3 major approaches to advance acute pancreatitis treatments—the clinical identification and application of new genetic information; newly identified serum biomarkers, i.e., fatty acid ethyl esters (FAEEs); and acceleration in timing of early nutrition feedings in acute pancreatitis. Clinical Identification and Application of New Genetic Information: When acute pancreatitis occurs at the age of 35 years or when it is relapsing or idiopathic, testing for the 6 commercially evaluable genetic causes of acute pancreatitis is recommended. This test provides valuable information regarding the diagnosis probability of genetic predisposition, cofactors that are likely to play a role in disease identification and a suitable approach to initiate treatment early in the process, without requiring repeated testing. Newly Identified Serum Biomarkers—FAEEs: During a prospective, blinded trial, researchers compared the levels of FAEE, nonesterified fatty acids, and ethanol in the blood of 175 patients hospitalized for alcoholic pancreatitis, alcohol intoxication, nonalcoholic pancreatitis, and normal controls. This test has the unique capability of demonstrating diagnostic elevations of FAEEs associated with alcohol consumption. Therefore, it can be evaluated that alcohol is the cause of alcohol-associated pancreatitis and to exclude it when there are other causes. Important Acceleration in Timing of Early Feedings in Acute Pancreatitis: The practice of beginning early feeding through the nasogastric/nasojejunal routes after the onset of acute pancreatitis has been supported by multiple randomized controlled trials and has replaced the practice of resting the gastrointestinal tract until pain subsides prior to feeding. This approach results in increased bowel motility and reduced organ failure, infection, length of stay, and mortality rates, confirming that an idle intestine leads to bacterial overgrowth, increased permeability, and bacterial translocation. Such developments in specific treatment approaches would lead to new treatment options to enhance outcomes and improve the North America acute pancreatitis market in the near future.
On the contrary, side effects of pancreatitis and pancreatic cancer treatments hampers on the growth of North America acute pancreatitis market.
Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held 56.6% share of North America acute pancreatitis market in 2022, amassing US$ 1,817.69 million. It is projected to garner US$ 2,805.77 million by 2030 to expand at 5.6% CAGR during 2022–2030.
Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held 45.7% share of North America acute pancreatitis market in 2022, amassing US$ 1,467.54 million. It is projected to garner US$ 2,354.55 million by 2030 to expand at 6.1% CAGR during 2022–2030.
Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held 75.4% share of North America acute pancreatitis market in 2022, amassing US$ 2,419.26 million. It is projected to garner US$ 3,745.25 million by 2030 to expand at 5.6% CAGR during 2022–2030.
Based on country, the North America acute pancreatitis market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 89.7% share of North America acute pancreatitis market in 2022. It was assessed at US$ 2,879.68 million in 2022 and is likely to hit US$ 4,450.63 million by 2030, exhibiting a CAGR of 5.6% during 2022–2030.
Key players operating in the North America acute pancreatitis market are Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare, among others.
In May 2023, GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. Precision DL provides the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratio, contrast recovery, and quantitative accuracy.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America acute pancreatitis market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in North America acute pancreatitis market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 North America Acute Pancreatitis Market, by Country (US$ Million)
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Acute Pancreatitis Market Landscape
4.1 Overview
5. North America Acute Pancreatitis Market – Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis
5.1.2 Rising Incidence of Diabetes Following Acute Pancreatitis
5.2 Key Market Restraints
5.2.1 Side Effects of Pancreatitis and Pancreatic Cancer Treatments
5.3 Key Market Opportunities
5.3.1 Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis
5.4 Future Trends
5.4.1 Advancements in Specific Acute Pancreatitis Treatments
5.5 Impact Analysis:
6. Acute Pancreatitis Market – North America Market Analysis
6.1 North America Acute Pancreatitis Market Revenue (US$ Mn), 2022 – 2030
7. North America Acute Pancreatitis Market – Revenue and Forecast to 2030 – by Offerings
7.1 Overview
7.2 North America Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
7.3 Medications
7.3.1 Overview
7.3.2 Medications: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 North America Acute Pancreatitis Market, by Medications, 2020–2030 (US$ Million)
7.4 Diagnosis
7.4.1 Overview
7.4.2 Diagnosis: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 North America Acute Pancreatitis Market, by Diagnosis, 2020–2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Acute Pancreatitis Market – Revenue and Forecast to 2030 – by Causes
8.1 Overview
8.2 North America Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
8.3 Gallstones
8.3.1 Overview
8.3.2 Gallstones: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Alcoholism
8.4.1 Overview
8.4.2 Alcoholism: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Genetic Disorders
8.5.1 Overview
8.5.2 Genetic Disorders: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Infections
8.6.1 Overview
8.6.2 Infections: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Acute Pancreatitis Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 North America Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Ambulatory Surgical Centers
9.5.1 Overview
9.5.2 Ambulatory Surgical Centers: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Acute Pancreatitis Market – Country Analysis
10.1 Overview
10.1.1.1 North America Acute Pancreatitis Market, by Country
10.1.1.2 US
10.1.1.2.1 Overview
10.1.1.2.2 US: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.3 US: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.2.3.1 US: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.2.3.2 US: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.2.4 US: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.2.5 US: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
10.1.1.3 Canada
10.1.1.3.1 Overview
10.1.1.3.2 Canada: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.3 Canada: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.3.3.1 Canada: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.3.3.2 Canada: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.3.4 Canada: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.3.5 Canada: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
10.1.1.4 Mexico
10.1.1.4.1 Overview
10.1.1.4.2 Mexico: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.3 Mexico: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.4.3.1 Mexico: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.4.3.2 Mexico: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.4.4 Mexico: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.4.5 Mexico: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
11. North America Acute Pancreatitis Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the North America Acute Pancreatitis Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 GE HealthCare Technologies Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Samsung Healthcare
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Koninklijke Philips NV
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Baxter International Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Dynavax Technologies Corp
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Medtronic Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Boston Scientific Corp
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Fresenius Kabi AG
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Acute Pancreatitis Market Segmentation
Table 2. North America Acute Pancreatitis Market, by Medications – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Acute Pancreatitis Market, by Diagnosis – Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Acute Pancreatitis Market, by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America Acute Pancreatitis Market, For Medications by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Acute Pancreatitis Market, For Diagnosis by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 7. US: North America Acute Pancreatitis Market, by Causes – Revenue and Forecast to 2030 (US$ Million)
Table 8. US: North America Acute Pancreatitis Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America Acute Pancreatitis Market, by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America Acute Pancreatitis Market, For Medications by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada: North America Acute Pancreatitis Market, For Diagnosis by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada: North America Acute Pancreatitis Market, by Causes – Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada: North America Acute Pancreatitis Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America Acute Pancreatitis Market, by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico: North America Acute Pancreatitis Market, For Medications by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico: North America Acute Pancreatitis Market, For Diagnosis by Offerings – Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico: North America Acute Pancreatitis Market, by Causes – Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico: North America Acute Pancreatitis Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the North America Acute Pancreatitis Market
Table 20. Recent Organic Growth Strategies in the North America Acute Pancreatitis Market
Table 21. Glossary of Terms, North America Acute Pancreatitis Market
LIST OF FIGURES
Figure 1. North America Acute Pancreatitis Market Segmentation, By Country
Figure 2. North America Acute Pancreatitis Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Acute Pancreatitis Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
Figure 6. Medications: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Diagnosis: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
Figure 10. Gallstones: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Alcoholism: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Genetic Disorders: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Infections: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. North America Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
Figure 16. Hospitals: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Diagnostic Laboratories: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Ambulatory Surgical Centers: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. North America Acute Pancreatitis Market, by Key Country – Revenue (2022) (US$ Million)
Figure 21. North America Acute Pancreatitis Market, By Key Countries, 2022 and 2030 (%)
Figure 22. US: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Canada: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Mexico: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Growth Strategies in the North America Acute Pancreatitis Market
The List of Companies – North America Acute Pancreatitis Market
o Abbott Laboratories
o Baxter International Inc
o Boston Scientific Corp
o Dynavax Technologies Corp
o Fresenius Kabi AG
o GE HealthCare Technologies Inc
o Koninklijke Philips NV
o Medtronic Plc
o Samsung Healthcare
You must be logged in to post a review.
Reviews
There are no reviews yet.